Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials

This systematic review investigates whether clinical trials of psilocybin support criterion number three the drug's schedule I designation: There is a lack accepted safety for use drug or other substance under medical supervision. Data were collected by using PubMed database and conducting search on November 24, 2021, with term applying trial filter. Only primary reports sole administration professional included analysis, excluding wherein was not administered, exclusively co-administered drugs, articles that trials, repeat analyses already trials. 52 publications closely examined adverse events, tolerability, safety. Zero these reported to be unsafe, while 27 suggested safe administer proper